Kreitzer Anatol 4
4 · MapLight Therapeutics, Inc. · Filed Apr 17, 2026
Research Summary
AI-generated summary of this filing
MapLight (MPLT) CDO Anatol Kreitzer Sells 3,316 Shares
What Happened
Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics (MPLT), sold 3,316 shares on April 15, 2026. The weighted average sale price was $26.61 per share, for total proceeds of roughly $88,239. This was a sale (not a purchase) and appears to be a routine disposition to satisfy tax withholding obligations related to vested restricted stock units.
Key Details
- Transaction date: 2026-04-15; Form 4 filed 2026-04-17 (timely filing).
- Transaction type/code: Sale (S) — open market or private sale (reported as S).
- Shares sold: 3,316; weighted average price: $26.61; total proceeds: ~$88,239.
- Price range: $26.6045 to $26.6093 across multiple trades (footnote F2). The filer can provide per-trade breakdown on request.
- Footnote F1: Sale represents shares sold to cover statutory tax withholding for vested RSUs.
- Shares owned after the transaction: Not specified in the provided filing excerpt.
Context
Because the sale was made to cover tax withholding on vested awards (per F1), it is generally considered a routine administrative sale rather than a directional bet on the company. No option exercise or gifting was involved; the filing indicates multiple small trades aggregated into a weighted average price.
Insider Transaction Report
- Sale
Voting Common Stock
[F1][F2]2026-04-15$26.61/sh−3,316$88,239→ 256,612 total
Footnotes (2)
- [F1]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.6045 to $26.6093 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.